Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a personalized antisense oligonucleotide therapy studied in a single participant with a PRPH2 mutation causing retinal dystrop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Dystrophy

Drugs mentioned

• PRPH2-targeted antisense oligonucleotide (antisense oligonucleotide targeting PRPH2)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Retinal Dystrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING